A5.12.14 [5.12.14] (ATCC® HB-11553)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  /  Cell Type: hybridoma:lymphoblast B lymphocyte; somatic cell hybri  / 

Permits and Restrictions

View Permits

Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Cell Type hybridoma:lymphoblast B lymphocyte; somatic cell hybri
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Strain

Strain: BALB/c (B cell); BALB/c (myeloma)

Storage Conditions liquid nitrogen vapor phase
Images
Derivation
Animals were immunized with recombinant human interleukin 8 (IL-8). Spleen cells were fused with P3X63Ag8U.1 (ATCC CRL-1597) mouse myeloma cells. The antibody blocks IL-8 binding to human neutrophil receptors. An expression plasmid pantilL-8.2 (ATCC 9056) was created to code for a chimeric murine-human fab fragment of the monoclonal antibody.
Genes Expressed
immunoglobulin; monoclonal antibody; against human interleukin 8 (IL-8)
Cellular Products
immunoglobulin; monoclonal antibody; against human interleukin 8 (IL-8)
Comments
Animals were immunized with recombinant human interleukin 8 (IL-8). Spleen cells were fused with P3X63Ag8U.1 (ATCC CRL-1597) mouse myeloma cells. The antibody blocks IL-8 binding to human neutrophil receptors. An expression plasmid pantilL-8.2 (ATCC 9056) was created to code for a chimeric murine-human fab fragment of the monoclonal antibody.
Complete Growth Medium The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Protocol: Cultures can be maintained by addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 5 x 10(5) viable cells/ml. Do not allow the cell concentration to exceed 5 X 10(5) cells/ml.
Interval: Maintain cultures at a cell concentration between 3 X 10(4) and 4 X 10(5) cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cryopreservation
Freeze medium: Complete growth medium described above supplemented with 5% (v/v) DMSO.
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Isotype mouse IgG2a kappa
Name of Depositor Genentech, Inc.
U.S. Patent Number
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished.
References

Fong S, et al. Anti-IL-8 antibody fragments. US Patent 5,677,426 dated Oct 14 1997

Hsei V, et al. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,468,532 dated Oct 22 2002

Hsei V, et al. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,458,355 dated Oct 1 2002

Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,133,426 dated Oct 17 2000

Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,117,980 dated Sep 12 2000

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation
References

Fong S, et al. Anti-IL-8 antibody fragments. US Patent 5,677,426 dated Oct 14 1997

Hsei V, et al. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,468,532 dated Oct 22 2002

Hsei V, et al. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,458,355 dated Oct 1 2002

Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,133,426 dated Oct 17 2000

Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,117,980 dated Sep 12 2000